| Literature DB >> 34430605 |
Wenfu Hu1, Binghui Qiu1, Fen Mei1, Jian Mao1, Lizhi Zhou2, Fan Liu1, Jun Fan1, Yi Liu1, Ge Wen3, Songtao Qi1, Yun Bao1, Jun Pan1.
Abstract
BACKGROUND: An assessment of the clinical impact for craniopharyngiomas (CPs) classification based on origin location has not been reported. The aim of this study was to determine the clinical impact of the site of tumor origin in primary CPs.Entities:
Keywords: Craniopharyngioma (CP); classification; origin location; outcome
Year: 2021 PMID: 34430605 PMCID: PMC8350632 DOI: 10.21037/atm-21-2924
Source DB: PubMed Journal: Ann Transl Med ISSN: 2305-5839
Figure 1Classification of CPs based on origin location. (A) Several possible sites of tumor origin are indicated as Q (black dots), S (yellow dots), and T (red dots); (B1) preoperative contrast-enhanced MR images of type Q CP; (B2) the relationship between type Q tumors and surrounding structures; (C1) preoperative contrast-enhanced MR images of type S CP; (C2) the relationship between type S tumors and surrounding structures; (D1) preoperative contrast-enhanced MR images of type T CP; (D2) the relationship between type T tumors and surrounding structures. White dots represent the origin point, green lines represent the arachnoid membrane, blue lines represent the dura mater, and violet lines represent the ependyma.
Preoperative clinical characteristics of patients, stratified according to growth pattern types
| Parameter | Type Q (n=142) | Type S (n=115) | Type T (n=272) | Total (n=529) | P value |
|---|---|---|---|---|---|
| Age at diagnosis | |||||
| Mean | 15.18±14.96 | 34.90±18.97 | 29.30±19.89 | 26.73±19.86 | <0.001 |
| Range | 2–60 | 3–67 | 2–72 | 2–72 | |
| Children, ≤14 yrs n (%) | 93 (65.5) | 24 (20.9) | 103 (37.9) | 220 (41.6) | <0.001 |
| Adults, >14 yrs n (%) | 49 (34.5) | 91 (79.1) | 169 (62.1) | 309 (58.4) | |
| Sex, n (%) | |||||
| Male | 93 (62.7) | 63 (55.7) | 173 (64.7) | 329 (62.2) | 0.168 |
| Female | 49 (37.3) | 52 (44.3) | 99 (35.3) | 200 (37.8) | |
| Tumor size (cm) | 3.7±1.3 | 3.9±1.0 | 3.6±1.0 | 3.7±1.1 | 0.028 |
| Follow-up (months) | |||||
| Mean | 106.8±48.0 | 102.8±38.4 | 100.0±43.8 | 102.4±43.9 | 0.325 |
| Range | 17–236 | 56–196 | 3–232 | 3–236 | |
| Hydrocephalus, n (%) | |||||
| None | 128 (90.1) | 98 (85.2) | 139 (51.1) | 365 (69.0) | <0.001 |
| Yes | 14 (9.9) | 17 (14.8) | 133 (48.9) | 164 (31.0) | |
| Tumor consistency, n (%) | |||||
| Solid | 18 (12.7) | 15 (13.1) | 36 (14.0) | 71 (13.4) | 0.695 |
| Mixed | 93 (65.5) | 77 (66.9) | 164 (60.3) | 334 (63.1) | |
| Cystic | 31 (21.8) | 23 (20.0) | 70 (25.7) | 124 (23.4) | |
| Pathology, n (%) | |||||
| Adamantinomatous | 142 (100.0) | 102 (88.7) | 235 (86.4) | 479 (90.5) | <0.001 |
| Papillary | 0 (0.0) | 13 (11.3) | 37 (13.6) | 50 (9.5) |
Presenting symptoms in craniopharyngioma, stratified according to growth pattern types
| Symptoms (No.) | Type Q (n=142) | Type S (n=115) | Type T (n=272) | Total (n=529) | P value |
|---|---|---|---|---|---|
| Headache | 57 (40.1) | 39 (34.0) | 162 (59.6) | 258 (48.8) | <0.001 |
| Nausea or vomiting | 9 (6.3) | 14 (12.2) | 89 (32.7) | 112 (21.2) | <0.001 |
| Diplopia | 32 (22.5) | 13 (11.3) | 10 (3.7) | 55 (10.4) | <0.001 |
| Reduced vision | 75 (52.8) | 75 (65.2) | 98 (36.0) | 248 (46.9) | <0.001 |
| Reduced visual field | 47 (33.1) | 63 (54.8) | 80 (29.4) | 190 (35.9) | <0.001 |
| Seizures | 5 (3.5) | 4 (3.5) | 8 (2.9) | 17 (3.2) | <0.001 |
| Loss of appetite | 10 (7.0) | 8 (7.0) | 8 (2.9) | 26 (4.9) | <0.001 |
| Weight loss | 4 (2.8) | 3 (2.6) | 8 (2.9) | 15 (2.8) | 0.984 |
| Polyuria | 17 (12.0) | 6 (5.2) | 41 (15.1) | 64 (12.1) | 0.025 |
| Growth retardation* | 78 (83.9) | 9 (37.5) | 46 (44.6) | 133 (60.5) | <0.001 |
| Weight gain | 5 (3.5) | 4 (3.5) | 34 (12.5) | 43 (8.1) | 0.001 |
| Insomnia | 5 (3.5) | 0 (0.0) | 10 (3.7) | 15 (2.8) | 0.117 |
| Altered personality | 1 (0.7) | 2 (1.7) | 10 (3.7) | 13 (2.5) | 0.008 |
| Memory impairment | 5 (3.5) | 4 (3.5) | 30 (11.0) | 39 (7.4) | 0.004 |
| Concentration impairment | 1 (0.7) | 4 (3.5) | 26 (9.6) | 31 (5.9) | 0.001 |
| Reduced consciousness | 0 (0.0) | 4 (3.5) | 20 (7.4) | 24 (4.5) | 0.002 |
*, only in age ≤14 years group, n=220 (type Q =93, type S =24, type T =103).
Presenting symptoms and surgical outcome in craniopharyngioma, stratified according to growth pattern type
| Parameter | Type Q (n=142) | Type S (n=115) | Type T (n=272) | Total (n=529) | P value |
|---|---|---|---|---|---|
| Preoperative Pituitary dysfunction axes, n (%) | |||||
| 0 axis | 4 (2.8) | 51 (44.3) | 72 (26.5) | 127 (24.0) | <0.001 |
| 1–2 axes | 35 (24.6) | 44 (38.3) | 130 (47.8) | 209 (39.5) | |
| 3–4 axes | 103 (72.5) | 20 (17.4) | 70 (25.7) | 193 (36.5) | |
| Preoperative polyuria | 17 (12.0) | 6 (5.2) | 41 (15.1) | 64 (12.1) | 0.025 |
| Postoperative pituitary dysfunction axes, n (%) | |||||
| 0 axis | 1 (0.01) | 31 (27.0) | 51 (18.6) | 83 (15.7) | <0.001 |
| 1–2 axes | 22 (15.5) | 57 (49.6) | 121 (44.5) | 200 (37.8) | |
| 3–4 axes | 119 (83.8) | 27 (23.5) | 100 (36.8) | 246 (46.5) | |
| Postoperative polyuria | 82 (57.7) | 47 (40.8) | 137 (50.4) | 266 (50.3) | 0.027 |
| Surgical approach, n (%) | |||||
| Frontal base interhemispheric | 50 (35.2) | 25 (21.7) | 161 (59.2) | 236 (44.6) | <0.001 |
| Pterion | 54 (38.0) | 73 (63.5) | 69 (25.4) | 196 (37.1) | |
| Transsphenoidal | 38 (26.8) | 7 (6.1) | 6 (2.2) | 51 (9.6) | |
| Lateral ventricle | 0 (0.0) | 2 (1.7) | 4 (1.5) | 6 (1.1) | |
| Transcallosal | 0 (0.0) | 8 (7.0) | 32 (11.8) | 40 (7.6) | |
| Functional outcome, n (%) | |||||
| Good | 121 (85.2) | 103 (89.6) | 209 (76.8) | 433 (81.9) | 0.006 |
| Poor | 21 (14.8) | 12 (10.4) | 63 (23.2) | 96 (18.1) |
Figure 2Graph depicting survival times in patients. All P values are based on log-rank test. (A) The image is related to the recurrence-free survival rate based on tumor origin location; (B) the image is related to the recurrence-free survival rate based on treatment modality; (C) the image is related to the overall-free survival rate based on tumor origin location; (D) the image is related to the overall-free survival rate based on treatment modality in Type T CP. GTR, gross total removal; STR, subtotal removal; RT, radiotherapy.